Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Greenwood Genetic Center Diagnostic Laboratories, |
RCV000677628 | SCV002568123 | pathogenic | Intellectual disability, autosomal dominant 50 | 2022-05-10 | criteria provided, single submitter | clinical testing | PVS2, PS2, PS4, PM2 |
Ambry Genetics | RCV004957982 | SCV005458517 | pathogenic | Inborn genetic diseases | 2024-07-19 | criteria provided, single submitter | clinical testing | The c.1009_1012delGAAA (p.E337Rfs*5) alteration, located in exon 9 (coding exon 9) of the NAA15 gene, consists of a deletion of 4 nucleotides from position 1009 to 1012, causing a translational frameshift with a predicted alternate stop codon after 5 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been determined to be the result of a de novo mutation in multiple individuals with features consistent with NAA15-related neurodevelopmental disorder (Zaidi, 2013; Cheng, 2018; Ritter, 2021). Functional analysis of patient derived cells showed degradation of the mutant NAA15 mRNA, suggesting nonsense-mediated decay (Cheng, 2018). Based on the available evidence, this alteration is classified as pathogenic. |
OMIM | RCV000677628 | SCV000803757 | pathogenic | Intellectual disability, autosomal dominant 50 | 2021-07-07 | no assertion criteria provided | literature only |